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In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol National Units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA. 
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA) 
and the European Commission.
In March 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-
2-carboxamide, commonly known as tetrahydrofuranylfentanyl 
(THF-F), through a joint assessment based upon the following 
criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on tetrahydrofuranylfentanyl satisfied criteria 4 and 
6. The two agencies therefore concluded that sufficient 
information had been accumulated to merit the production of 
a Joint Report on tetrahydrofuranylfentanyl as stipulated by 
Article 5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
25 April 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on tetrahydrofuranylfentanyl, 
in order to prepare the Joint Report. The information was 
collected mainly through the Reitox national focal points in the 
Member States, Turkey and Norway as well as the Europol 
National Units. In addition, the EMA collected information 
through the national competent authorities responsible for 
human and veterinary medicinal products in the Member 
States as well as in Norway, Iceland and Liechtenstein. The 
EMA also provided information as relevant to the centralised 
procedure for authorising medicinal products. The information 
collection process was largely concluded by 6 June 2017.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of tetrahydrofuranylfentanyl in their 
country;
 ¡ the level of distribution of tetrahydrofuranylfentanyl in their 
country;
 ¡ the level of trafficking of tetrahydrofuranylfentanyl in their 
country, both for internal, transit or export purposes;
 ¡ the number of seizures of tetrahydrofuranylfentanyl in their 
country, the total amount of the seizures, country of origin, 
details on the physical forms (including photos);
 ¡ the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of 
tetrahydrofuranylfentanyl in their country; and,
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of 
tetrahydrofuranylfentanyl.
Europol received responses from 16 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein, provide information 
on whether:
 ¡ the new psychoactive substance tetrahydrofuranylfentanyl 
has obtained a marketing authorisation;
 ¡ the new psychoactive substance tetrahydrofuranylfentanyl 
is the subject of an application for a marketing 
authorisation; and,
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance 
tetrahydrofuranylfentanyl has been suspended.
Twenty-three countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
(2) In alphabetical order: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia, Slovenia and Spain.
(3) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Latvia, the Netherlands, Norway, Poland, Spain, Sweden and the United 
Kingdom provided a response in relation to human and veterinary medicinal 
products. Croatia, Czech Republic and Italy provided a response in relation to 
human medicinal products. France, Portugal, Slovakia and Slovenia provided 
a response in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council Decision 
in relation to the manufacturing of medicinal products in the 
European Union, the EMA also requested information on whether 
the new psychoactive substance tetrahydrofuranylfentanyl is 
used to manufacture a medicinal product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation; and,
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-three countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from 27 Member 
States (5), as well as Turkey and Norway;
 ¡ reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not tetrahydrofuranylfentanyl is 
under assessment by the United Nations system; and,
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’) and, online vendors 
selling tetrahydrofuranylfentanyl.
The EMCDDA would like to thank the United States Drug 
Enforcement Administration for kindly providing unpublished 
in vitro data on the pharmacology of tetrahydrofuranylfentanyl 
(US DEA, 2017).
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included 
in sections 3.8.3 (in part) and 4 was provided by the EMA.
(4) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Latvia, the Netherlands, Norway, Poland, Spain, Sweden and the United 
Kingdom provided a response in relation to human and veterinary medicinal 
products. Croatia, Czech Republic and Italy provided a response in relation to 
human medicinal products. France, Portugal, Slovakia and Slovenia provided 
a response in relation to veterinary medicinal products.
(5) A reply was not received from Slovakia. 
 3.  Information required by Article 5.2 
of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1  Chemical and physical description, including 
the names under which the new psychoactive 
substance is known (Article 5.2(a) of 
the Council Decision)
Chemical description and names
Tetrahydrofuranylfentanyl (THF-F) belongs to the 
4-anilidopiperidine class of synthetic opioids. This class also 
includes fentanyl (6), which is internationally controlled and 
a number of other fentanils.
A total of 15 fentanils are controlled under the United Nations 
Single Convention on Narcotic Drugs, 1961, as amended by 
the 1972 Protocol (7).
Tetrahydrofuranylfentanyl differs from fentanyl due to the 
presence of a tetrahydrofuran ring in place of an ethyl group 
attached to the carbonyl. Tetrahydrofuranylfentanyl is closely 
related to furanylfentanyl (8), which has been subjected to risk 
assessment by the EMCDDA (EMCDDA, 2017). It differs from 
furanylfentanyl by bearing a fully saturated furanyl ring 
(tetrahydrofuran), instead of an unsaturated ring (furan).
The molecular structure, molecular formula, and molecular 
mass of tetrahydrofuranylfentanyl are provided in in Figure 1.
(6) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide. 
(7) 3-Methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-methylfentanyl, 
alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-methylfentanyl, 
beta-hydroxyfentanyl, para-fluorofentanyl, thiofentanyl, acetylfentanyl and 
butyrfentanyl are controlled under Schedule I and IV; alfentanil, fentanyl, 
sufentanil and remifentanil are controlled under Schedule I.
(8) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide 
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Tetrahydrofuranylfentanyl has one positional isomer, which is 
3-tetrahydrofuranylfentanyl. In 3-tetrahydrofuranylfentanyl, 
the carboxamide is attached to the 3-position of the furan 
ring (9).
Tetrahydrofuranylfentanyl contains a stereogenic centre thus 
allowing for the existence of a pair of enantiomers (10), 
(S)-tetrahydrofuranylfentanyl and (R)-
tetrahydrofuranylfentanyl. There is no information on the 
actual enantiomer found in the European drug market.
The synthesis of tetrahydrofuranylfentanyl has not been 
described in the literature.
Commonly used names:  
tetrahydrofuranylfentanyl or THF-F 
Systematic (IUPAC) name:  
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-
2-carboxamide
Other chemical names:  
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-
carboxamide;  
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
carboxamide;  
N-fenyl-N-[1-(2-fenyletyl)piperidin-4-yl]tetrahydrofuran-2-
karboxamid (Swedish)
(9) Note that although ‘tetrafuranylfentanyl’ can refer to 2- and to 3- 
tetrafuranylfentanyl, in this report it will reference the 2-isomer.
(10) Enantiomers are pairs of molecules that are mirror images of each other and 
therefore not superimposable. Although they have the same two dimensional 
molecular structure, enantiomers can exhibit marked differences in biological 
activity including pharmacological effects.
Other names and code names:  
tetrahydrofuranfentanyl; tetrahydrofuran fentanyl; 
tetrahydrofuranyl fentanyl; tetrahydrofuran-fentanyl;  
THF-F; THF-fentanyl; tetrahydrofuran-F; Tetra
Chemical Abstracts Service (CAS) registry numbers (11):  
not registered
IUPAC International Chemical Identifier Key (InCHI Key) (12):  
OHJNHKUFSKAANI-UHFFFAOYSA-N
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
hits.
Physical description
Tetrahydrofuranylfentanyl contains one basic nitrogen atom in 
the piperidine ring which can readily form salts with organic or 
inorganic acids.
There is no solubility data on tetrahydrofuranylfentanyl or its 
hydrochloride salt; due to its similarity to fentanyl, the free 
base could be expected to be sparingly soluble in water; the 
hydrochloride and citrate salt could be expected to have 
greater aqueous solubility.
Tetrahydrofuranylfentanyl is expected to be lipophilic.
(11) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(12) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
FIGURE 1 
Molecular structure, molecular formula and molecular mass of tetrahydrofuranylfentanyl. Information on furanylfentanyl and 
fentanyl is provided for comparison.
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Tetrahydrofuranylfentanyl has been seized as a liquid and in 
powder form. A more detailed description of seizures and 
collected samples can be found in section 3.2.1 and section 3.2.2.
Detection and analysis
Methods documented in the literature for the detection of 
tetrahydrofuranylfentanyl include: gas chromatography – 
mass spectrometry (GC-MS), high performance liquid 
chromatography time-of-flight (HPLC-TOF), Fourier transform 
infrared spectroscopy attenuated total reflectance (FTIR-ATR) 
and gas chromatography – mass spectrometry – infrared 
spectroscopy (GC-(MS)-IR) condensed phase (Slovenian 
National Forensic Laboratory, 2017).
The implementation of chromatographic techniques, infrared 
and nuclear magnetic resonance (NMR) spectrometry allow 
unambiguous differentiation between 2- and 
3-tetrahydrofuranylfentanyl. As of June 2017, the detection of 
3-tetrahydrofuranylfentanyl in Europe has not been reported 
to the EMCDDA.
It is possible that immunoassays for fentanyl may not 
distinguish between tetrahydrofuranylfentanyl and fentanyl 
due to the structural similarity between the two substances 
(US DEA, 2016a). Identification of tetrahydrofuranylfentanyl 
therefore would require further confirmatory analysis, such as 
mass spectrometry (US DEA, 2016a). Similarly, 
tetrahydrofuranylfentanyl is not expected to give a positive 
response to tests developed for morphine-type opioids. There 
is no information on the reaction of tetrahydrofuranylfentanyl 
to presumptive colour tests.
 3.2  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on the 
means and methods of manufacture of the new 
psychoactive substance (Article 5.2(b) of the 
Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 16 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, 
Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia, Slovenia and Spain).
Fifteen countries reported that they have no available 
information on tetrahydrofuranylfentanyl (Austria, Belgium, 
Bulgaria, Croatia, Cyprus, Czech Republic, Finland, Germany, 
Greece, Latvia, Lithuania, Luxembourg, Romania, Slovakia and 
Spain).
Slovenia provided information on a collected sample 
(section 3.2.2).
The level of production
No information was received in relation to the production of 
tetrahydrofuranylfentanyl.
The level of distribution
No information was received in relation to the distribution 
(seizures) of tetrahydrofuranylfentanyl.
The level of trafficking
No information was received in relation to the trafficking of 
tetrahydrofuranylfentanyl.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from the 27 Member 
States (5), as well as from Turkey and Norway. Of these, two 
Member States (Slovenia and Sweden) reported detections of 
tetrahydrofuranylfentanyl (13).
It is important to note that detections of 
tetrahydrofuranylfentanyl may be under-reported since the 
substance is not routinely screened for. Three Member States 
(Austria, Slovenia and Sweden) reported that 
tetrahydrofuranylfentanyl is part of routine screening in some 
(but not all) laboratories.
Seizures
In total, 43 seizures of tetrahydrofuranylfentanyl were reported 
to the EMCDDA, all by Sweden. Where reported, the seizures 
were made by the police. Of these, 26 seizures took place in 
2016, while the remaining 17 took place in 2017.
Seizures of tetrahydrofuranylfentanyl included:
 ¡ 41 seizures of liquids, amounting to a total of 698.5 mL;
 ¡ 2 seizures of powders, amounting to a total of 1.57 g.
(13) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
7 / 13
JOINT REPORTS I THF-F
In all the cases, tetrahydrofuranylfentanyl was the sole 
substance detected. No quantitative information on purity was 
reported.
Collected samples
One collected sample was reported by Slovenia, which 
consisted of 5 g of powder test-purchased from the internet 
from a site based in China. In the sample, 4-aminophenyl-1-
phenethylpiperidine (4-ANPP) was also detected.
Biological samples
Serious adverse events with confirmed exposure to 
tetrahydrofuranylfentanyl from biological samples are 
discussed in section 3.4.2.
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of 
the Council Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the 
tetrahydrofuranylfentanyl was provided.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of 
tetrahydrofuranylfentanyl.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of tetrahydrofuranylfentanyl.
 3.4  A first indication of the risks associated with the 
new psychoactive substance, including the health 
and social risks, and of the characteristics of 
users — Article 5.2(d) of the Council Decision
3.4.1 Health risks
Pharmacology and toxicology
Limited data suggests that tetrahydrofuranylfentanyl is 
a μ-opioid receptor agonist that shares some similarities with 
opioid analgesics such as morphine and fentanyl (US DEA, 
2017 (14)).
(14) Enantiomeric composition not specified.
The acute effects of these types of opioids include: euphoria, 
relaxation, analgesia, sedation, bradycardia, hypothermia and 
respiratory depression. They also have an abuse liability and 
dependence potential (Herz, 1993; Kieffer, 1999, Pasternak 
and Pan, 2013; Pattinson, 2008; Romberg et al., 2003).
Similar to other opioid analgesics, the most serious acute 
health risk from using tetrahydrofuranylfentanyl is probably 
respiratory depression, which in overdose could lead to 
apnoea, respiratory arrest and death (EMCDDA, 2017; 
Pattinson, 2008; White and Irvine, 1999). This risk may be 
greater due to: the difficulty in diluting the substance; a lack of 
experience with its effects and dosing; the use of other central 
nervous system depressants at the same time (such as other 
opioids, benzodiazepines, gabapentanoids and alcohol); a lack 
of tolerance to opioids; and, using the substance alone (such 
as at home) which would make it more difficult for users to call 
for help in the case of poisoning.
The antidote naloxone should reverse acute poisoning caused 
by tetrahydrofuranylfentanyl (Kim and Nelson, 2015; Ujváry et 
al., 2017). Recent clinical and community experience in 
treating poisonings caused by fentanils suggests that larger 
than normal doses and repeated doses of naloxone may be 
required to fully reverse poisoning in some cases (EMCDDA, 
2017).
While there is limited data for tetrahydrofuranylfentanyl, the 
chronic health risks might share some similarities to opioids 
such as heroin and other fentanils. This may include 
dependence.
3.4.2 Serious adverse events
Acute intoxications reported to the EMCDDA
In total, one acute intoxication with confirmed exposure to 
tetrahydrofuranylfentanyl was reported by Sweden (15). 
The case occurred in 2016.
In this case, the patient had administered eight actuations of 
a ‘fentanyl’ nasal spray. The poisoning was classed as severe. 
The clinical features were consistent with the use of an opioid 
and included decreased consciousness, respiratory 
depression and miosis. Naloxone was administered but the 
response was not reported. The only other substance detected 
was flunitrazolam. The patient survived.
(15) In addition, Sweden also reported 2 acute intoxications with suspected 
exposure to tetrahydrofuranylfentanyl. These cases are not discussed further in 
this report.
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Deaths reported to the EMCDDA
In total, 14 deaths with confirmed exposure to 
tetrahydrofuranylfentanyl were reported by Sweden. The 
cases occurred between 2016 and 2017.
Of the deaths, eight were male (57 %) and six were female 
(43 %). The males were aged between 25 and 41 years (mean 
31.4, median 29); the females were aged between 29 and 38 
years (mean 31.5, median 30).
A range of other substances were detected in the deaths, 
including other central nervous system depressants. Other 
opioids were only detected in three cases. Where known, most 
of the individuals were found dead; in at least some cases this 
was in a home environment. In at least 12 cases, 
tetrahydrofuranylfentanyl was the cause of death or 
contributed to the death.
3.4.3 Characteristics of users
Similar to other new fentanils, tetrahydrofuranylfentanyl is 
sold and used a ‘legal’ substitute for illicit opioids and 
prescription opioids; this may include for self-medication, 
such as the alleviation of pain and/or opioid withdrawal. Users 
may include high-risk drug users as well as others (such as 
psychonauts) who may be experimenting with the substance.
3.4.4 Social risks
While there is limited data for tetrahydrofuranylfentanyl, the 
social risks might share some similarities with opioids such as 
heroin and other fentanils.
Of additional note is that, in the past few years, fentanils have 
been sold in Europe as ready-to-use nasal sprays and e-liquids 
for vaping. In general, these novel products could make it 
easier to use such substances (with similar effects to 
injecting) and make them more socially acceptable.
Similar to other fentanils, accidental exposure to 
tetrahydrofuranylfentanyl may also pose a risk of severe 
poisoning. Those at risk may include the family and friends of 
users, law enforcement, emergency personnel, medical and 
forensic laboratory personnel, as well as those working in the 
postal services. Where required, these risks should be 
assessed and appropriate procedures, training and protective 
measures should be implemented. This may include training in 
resuscitation and adequate provision of the antidote naloxone.
 3.5  Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of 
the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 1 May 2017, the World Health Organization informed the 
EMCDDA that tetrahydrofuranylfentanyl is currently not under 
assessment and has not been under assessment by the UN 
system.
Since then, the World Health Organization has published a list 
of substances that will be reviewed at the 39th meeting of the 
WHO Expert Committee on Drug Dependence (ECDD) that 
will be held in November 2017. Tetrahydrofuranylfentanyl was 
included in the list of substances that will be reviewed. At the 
time of writing this report neither a critical review nor a written 
recommendation had been published.
 3.6  The date of notification on the Reporting Form of 
the new psychoactive substance to the EMCDDA 
or to Europol (Article 5.2(f) of the Council 
Decision)
The first official EMCDDA–Europol notification of 
tetrahydrofuranylfentanyl dates from 23 December 2016 from 
the Swedish national focal point. The Reporting Form details 
the seizure of tetrahydrofuranylfentanyl in 22 ml of pale yellow 
liquid, seized by Swedish Police in Karlstad on 29 September 
2016. The substance was analytically confirmed by GC-MS, 
liquid chromatography–high resolution mass spectrometry 
(LC–HRMS) and NMR by the Swedish National Forensic 
Centre. The formal notification informed on five analytically 
confirmed deaths associated with tetrahydrofuranylfentanyl 
that had occurred in Sweden between September and 
October 2016.
Tetrahydrofuranylfentanyl was added to the list of new 
psychoactive substances monitored by the EMCDDA and 
Europol through the European Union Early Warning System. 
A profile of the substance was created on the European 
Database on New Drugs (EDND). Since then, analytical details 
and other information, including a public health alert, have 
been exchanged between the EMCDDA, Europol, the Member 
States, Turkey and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
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 3.7  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Three Member States (Latvia, Sweden and the United 
Kingdom) reported that tetrahydrofuranylfentanyl is controlled 
under drug control legislation.
Two Member States (Austria and Poland) reported that 
tetrahydrofuranylfentanyl is controlled under specific new 
psychoactive substances control legislation.
Norway reported that tetrahydrofuranylfentanyl is controlled 
under medicines legislation.
Twenty two Member States (Belgium, Bulgaria, Croatia, 
Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Lithuania, 
Luxembourg, Malta, the Netherlands, Portugal, Romania, 
Slovenia and Spain) and Turkey reported that 
tetrahydrofuranylfentanyl is not subject to control measures at 
the national level.
Slovakia did not provide information on the control status of 
tetrahydrofuranylfentanyl.
 3.8  Further information (Article 5.2(h) of the 
Council Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey or 
Norway, about the chemical precursors or manufacturing 
methods used to make the tetrahydrofuranylfentanyl which 
has been detected within Europe.
In a collected sample reported by Slovenia, the precursor 
4-ANPP was also detected (section 3.2.2).
The synthesis of tetrahydrofuranylfentanyl has not been 
described in the literature. The manufacture of 
tetrahydrofuranylfentanyl relies on precursors and synthetic 
methods similar to those used for the manufacture of 
pharmaceutical fentanyl (Casy and Huckstep, 1988; Gupta et 
al., 2013; Zee and Wang, 1980). Therefore the methods 
developed for the synthesis of fentanyl are applicable to the 
synthesis of tetrahydrofuranylfentanyl. Use of a different 
acylating agent in the final acylation step, such as 
tetrahydrofuranoyl chloride would produce 
tetrahydrofuranylfentanyl. A one-step method uses N-phenyl-
1-(2-phenylethyl)piperidin-4-amine (4-ANPP) and 
tetrahydrofuranoyl chloride for the manufacture of the 
substance.
Two potential precursors of fentanyl and other fentanils 
4-ANPP as well as N-phenethyl-4-piperidone (NPP, a pre-
precursor), have been recently scheduled under the United 
Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988 (16).
Most of the synthetic procedures are straightforward, use 
common laboratory equipment and precursors and detailed 
recipes are available on the internet (17). While only basic 
knowledge of synthetic chemistry is required, due to the 
potency of fentanils extreme caution is required when carrying 
out the final synthetic step as well as when purifying and 
handling the substance (18). Exposure of the skin and mucous 
membranes to fentanils as well as their inhalation pose 
a serious risk of accidental poisoning. In addition to exercising 
extreme caution, suitable personal protective equipment as 
well as sufficient stocks of naloxone as an antidote to 
poisoning following accidental exposure should be available 
when handling materials suspected to contain these 
substances (CDCP, 2013; US DEA, 2016b).
In summary, whilst the synthesis of tetrahydrofuranylfentanyl 
has not been described in the literature, other routes 
developed for the production of fentanyl may also be used for 
the manufacture of tetrahydrofuranylfentanyl. There is no 
information on the actual method(s) used for the production 
of tetrahydrofuranylfentanyl that has been detected in Europe 
to date.
3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of 
tetrahydrofuranylfentanyl. Given the limited information 
currently available, the relevant information has been included 
in the previous sections.
(16) Table I of the United Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988.
(17) The detailed description of the most common procedure, referred to as the 
‘Siegfried method’, is readily available on the internet (see, for example,  
http://opioids.com/fentanyl/synthesis.html).
(18) Self-educated clandestine chemists commented on the risk while discussing 
the synthesis of fentanyl and its potent 3-methyl and α-methyl homologues 
(comment was posted on 7 May, 2002); available at: https://the-hive.archive.
erowid.org/forum/showflat.pl?Cat=&Number=260275 (Accessed: 27 June 2017).
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3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that tetrahydrofuranylfentanyl had any 
other use apart from in analytical reference materials and 
scientific research.
From the available information, it does not appear that 
tetrahydrofuranylfentanyl is used in the manufacture of 
a medicinal product in the European Union. However, the data 
collection is incomplete and some countries indicated that 
this information is not known. It is understood that the 
collection of such information is a challenge in the absence of 
a database on the synthetic route of all medicinal products.
Ten countries (Austria, Belgium, Croatia, Denmark, Greece, 
Italy, the Netherlands, Poland, Spain and the United Kingdom) 
reported that tetrahydrofuranylfentanyl is not used to 
manufacture a medicinal product for human use. Nine 
countries (Czech Republic, Estonia, Finland, Germany, 
Hungary, Ireland, Latvia, Norway and Sweden) reported that it 
was unknown if tetrahydrofuranylfentanyl is used to 
manufacture a medicinal product for human use.
In addition, the EMA reported that it is not known if 
tetrahydrofuranylfentanyl is used in the manufacture of 
medicinal products for human use and which are centrally 
authorised within the European Union.
Ten countries (Austria, Belgium, Denmark, France, Greece, 
Latvia, Poland, Slovakia, Spain and the United Kingdom) 
provided information that tetrahydrofuranylfentanyl is not 
used to manufacture a medicinal product for veterinary use. 
Ten countries (Estonia, Finland, Germany, Hungary, Ireland, 
the Netherlands, Norway, Portugal, Slovenia and Sweden) 
reported that it was unknown if tetrahydrofuranylfentanyl is 
used to manufacture a medicinal product for veterinary use.
In addition, the EMA reported that it is not known if 
tetrahydrofuranylfentanyl is used in the manufacture of 
medicinal products for veterinary use and which are centrally 
authorised within the European Union.
 4.  Information from the EMA (Article 5.3 
of the Council Decision)
Nineteen countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, Spain, 
Sweden and the United Kingdom) reported that:
 ¡ tetrahydrofuranylfentanyl has not been granted a marketing 
authorisation as a medicinal product for human use;
 ¡ tetrahydrofuranylfentanyl is not the subject of an 
application for a marketing authorisation as a medicinal 
product for human use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to tetrahydrofuranylfentanyl as 
a human medicine.
Twenty countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Ireland, Latvia, 
the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, 
Spain, Sweden and the United Kingdom) reported that:
 ¡ tetrahydrofuranylfentanyl has not been granted a marketing 
authorisation as a medicinal product for veterinary use;
 ¡ tetrahydrofuranylfentanyl is not the subject of an 
application for a marketing authorisation as a medicinal 
product for veterinary use;
 ¡ that there had been no cases of suspended marketing 
authorisation in respect to tetrahydrofuranylfentanyl as 
a veterinary medicine.
The EMA also reported that tetrahydrofuranylfentanyl:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
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I 5. Conclusion
Tetrahydrofuranylfentanyl belongs to a group of synthetic 
opioids known as the fentanils. It is closely related to fentanyl, 
which is controlled under the United Nations Single 
Convention on Narcotic Drugs of 1961. Data suggests that 
tetrahydrofuranylfentanyl may be an opioid narcotic analgesic 
in humans and, as such, may have an abuse liability and 
dependence potential; these effects may be broadly 
comparable to fentanyl. The most serious acute health risk 
posed by tetrahydrofuranylfentanyl is likely to be respiratory 
depression, which in overdose can be life-threatening. The 
antidote naloxone should reverse acute poisoning.
Tetrahydrofuranylfentanyl has been available in the European 
Union since at least September 2016. It has been detected in 
one Member State where it has been seized as a liquid and 
a powder. The detected quantities are relatively small; 
however, they should be seen within the context of the high 
potency that is typical of the fentanils.
There are indications that the tetrahydrofuranylfentanyl 
currently available on the market is synthesised by chemical 
companies based in China. Tetrahydrofuranylfentanyl is sold 
online often under the guise of a ‘research chemical’. It is 
available in wholesale amounts and in consumer amounts.
Fourteen deaths with confirmed exposure to 
tetrahydrofuranylfentanyl have been reported by one Member 
State. In at least 12 of the deaths, tetrahydrofuranylfentanyl 
was the cause of death or contributed to the death.
Tetrahydrofuranylfentanyl is sold and used as a substitute for 
illicit opioids and prescription opioids. Similar to other 
fentanils, serious concerns exist that the substance could be 
supplied surreptitiously to a range of drug users.
Tetrahydrofuranylfentanyl is under assessment within the 
United Nations system. It will be reviewed at the 39th meeting 
of the WHO Expert Committee on Drug Dependence (ECDD) 
that will be held in November 2017. Currently, neither a critical 
review nor a written recommendation has been published. 
Tetrahydrofuranylfentanyl is not subject to control measures in 
22 Member States and Turkey.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of tetrahydrofuranylfentanyl 
and the involvement of organised crime and possible 
consequences of control measures, could be thoroughly 
assessed through a risk assessment procedure in accordance 
with Article 6 of Council Decision 2005/387/JHA.
The EMCDDA and Europol will continue to intensively monitor 
tetrahydrofuranylfentanyl in order to ensure that new 
information is provided to the Member States, the EMA and 
the Commission via the information exchange of the European 
Union Early Warning System.
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